NSPR

InspireMD Inc.

0.86 USD

Last updated Sep 4, 20:42 UTC

Yesterday HIGH

$0.9

Yesterday LOW

$0.84

52w HIGH

$2.56

52w LOW

$0.63

EPS

-0.17

PE

-5.07

Next Earnings

Nov 3, 2026

Overview News Government Trades Fundamentals

InspireMD Inc. stock is up 19.61% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 21.43% of the previous 13 September’s closed higher than August.

Benzinga Newsdesk

Tue May 5, 2026

Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.
Benzinga Insights

Mon May 4, 2026

Transcript: InspireMD Q1 2026 Earnings Conference Call
Benzinga Newsdesk

Mon May 4, 2026

InspireMD Q1 EPS $(0.16) Beats $(0.19) Estimate, Sales $3.398M Beat $2.698M Estimate

InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 27.27 percent increase over losses of $(0.22) per share from the
Benzinga Insights

Mon May 4, 2026

Earnings Scheduled For May 4, 2026
Benzinga Insights

Fri May 1, 2026

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Newsdesk

Fri May 1, 2026

InspireMD Withdraws Prior Full Year 2026 Revenue Guidance; Says Given The Impact Of The Temporary Discontinuation Of Commercial Activity In The U.S. Pending The Anticipated FDA Approval Of Its Original CGuard Stent Delivery System In Q3 2026

2026 Financial GuidanceConcurrent with today's announcement, the Company is withdrawing its prior full year 2026 revenue guidance. Management believes this is the most prudent step given the impact of the temporary
Benzinga Newsdesk

Fri May 1, 2026

InspireMD shares are trading higher after the company announced that the FDA approved its Investigational Device Exemption Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system.
Benzinga Newsdesk

Fri May 1, 2026

InspireMD Initiates Voluntary U.S. Recall Of CGuard Prime 135cm Carotid Stent Delivery System; Recall Follows Technical Performance Of CGuard Prime 135cm Not Meeting Expectations; Recall Does Not Include CGuard Stent Implant; FDA Approval Of CGuard Prime 80cm For TCAR Anticipated In 2H 2026; FDA Approval, U.S. Availability Of Original CGuard Delivery System Anticipated In Q3 2026; Implementing Design Improvements To CGuard Prime Stent Delivery System

- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% - - FDA approval anticipated with U.S. market availability of original CGuard delivery system in the third quarter of 2026 -
Benzinga Newsdesk

Fri May 1, 2026

InspireMD Says FDA Approves IDE Application To Initiate CGUARDIANS III Pivotal Study Of SwitchGuard NPS, Including Next Gen Enhancements From Prior IDE Approval For Use With CGuard Prime 80 cm Stent Platform, In TCAR Procedures

InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration ("FDA") has
Benzinga Insights

Thu Apr 23, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session

TSLA $353.91 USD

BETR BETR $14.46 USD

NTLA $12.75 USD

NVTS $11.81 USD

SNDK $1,738.83 USD

ASML $1,714.70 USD

MSTX MSTX $16.80 USD

SKHY SKHY $176.99 USD

IREN $44.64 USD

SMCI $39.60 USD